Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease and is considered the hepatic manifestation of metabolic syndrome, triggering out adverse outcomes. A stacked multimodal machine learning model is constructed and validated for early identification and prognosis stratification of NAFLD by integrating genetic and clinical data sourced from 36 490 UK Biobank and 9 007 Nanfang Hospital participants and extracted its probabilities as in-silico scores for NAFLD (ISNLD). The efficacy of ISNLD is evaluated for the early prediction of severe liver disease (SeLD) and analyzed its association with metabolism-related outcomes. The multimodal model performs satisfactorily in classifying individuals into low- and high-risk groups for NAFLD, achieving area under curves (AUCs) of 0.843, 0.840, and 0.872 within training, internal, and external test sets, respectively. Among high-risk group, ISNLD is significantly associated with intrahepatic and metabolism-related complications after lifestyle factors adjustment. Further, ISNLD demonstrates notable capability for early prediction of SeLD and further stratifies high-risk subjects into three risk subgroups of elevated risk for adverse outcomes. The findings emphasize the model's ability to integrate multimodal features to generate ISNLD, enabling early detection and prognostic prediction of NAFLD. This facilitates personalized stratification for NAFLD and metabolism-related outcomes based on digital non-invasive markers, enabling preventive interventions.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12412496PMC
http://dx.doi.org/10.1002/advs.202410527DOI Listing

Publication Analysis

Top Keywords

liver disease
16
early detection
8
prognosis stratification
8
nonalcoholic fatty
8
fatty liver
8
adverse outcomes
8
stratification nafld
8
early prediction
8
metabolism-related outcomes
8
nafld
6

Similar Publications

Prevalence and risk factors of metabolic dysfunction-associated steatotic liver disease in patients with inflammatory bowel disease.

Eur J Gastroenterol Hepatol

September 2025

Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, The University of Jordan, Jordan University Hospital.

Aim: The purpose of our study was to evaluate the prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) and its associated risk factors in patients with inflammatory bowel disease (IBD).

Methods: This was a retrospective chart review of patients who underwent treatment for IBD at Jordan University Hospital between January 2013 and 2022. Case finding methods and clinical chart reviews were used to evaluate the clinical profile of patients with IBD.

View Article and Find Full Text PDF

Bevacizumab for refractory gastrointestinal angiodysplasia: a case report and literature review.

Eur J Gastroenterol Hepatol

August 2025

Department of Gastroenterology and Hepatology, Noordwest Ziekenhuisgroep, Alkmaar.

Currently, symptomatic gastrointestinal (GI) angiodysplasia is treated with argon plasma coagulation (APC) via endoscopic procedures, supplemented with octreotide or thalidomide treatment. However, suboptimal response and side effects are often seen. Bevacizumab, an angiogenesis inhibitor, may provide an alternative systemic therapy for patients with refractory GI angiodysplasia.

View Article and Find Full Text PDF

Aims: We investigated the independent association between dietary vitamin E intake among individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) and all-cause and cause-specific mortality in a representative sample of the USA.

Methods: We used the 2007-2014 US National Health and Nutrition Examination Survey with mortality follow-up through 2019 (median: 8.6 years).

View Article and Find Full Text PDF

Predicting Unplanned Readmission Risk in Patients With Cirrhosis: Complication-Aware Dynamic Classifier Selection Approach.

JMIR Med Inform

September 2025

College of Medical Informatics, Chongqing Medical University, 1 Yixueyuan Road, Yuzhong District, Chongqing, 400016, China, 86 13500303273.

Background: Cirrhosis is a leading cause of noncancer deaths in gastrointestinal diseases, resulting in high hospitalization and readmission rates. Early identification of high-risk patients is vital for proactive interventions and improving health care outcomes. However, the quality and integrity of real-world electronic health records (EHRs) limit their utility in developing risk assessment tools.

View Article and Find Full Text PDF

Objective: To verify the effect of physical exercise on the quality of life of patients with liver cirrhosis (LC).

Methods: the sample included controlled and randomized experimental studies of individuals with LC, at any stage of the disease, over 18 years of age, of both sexes, who performed any type of physical exercise compared to any other intervention or no intervention, with quality of life as the outcome assessed by the Chronic Liver Disease Questionnaire (CLDQ). The search for articles was conducted in 11 databases.

View Article and Find Full Text PDF